Prostate Cancer Studies, Discoveries and Achievements
University Hospitals Prostate cancer research touches all aspects of the disease and patient journey. Our team conducts research in the following areas:
- Diagnosis: biopsy, imaging, semen diagnostics and blood
- Risk stratification: machine learning clinicopathologic models, AI digital pathology, radiomics and genomics
- Predictive biomarker development and validation: gene expression, genomics and AI digital pathology
- Clinical trials: phase 1-3, IIT, international randomized trials and NCTN (NRG, SWOG, ECOG) trials
- Health Disparities and Outreach: African American community outreach and interplay of social determinants of health and aging and biology
- Prospective biorepositories and patient registries
- Exercise oncology
- Big data/health services research
- Basic science- interplay of DNA repair and androgen signaling
- Cost effectiveness research
- Quality Improvement research
Trials, Studies, Discoveries and Achievements Articles
Showing of 18 results
University Hospitals Urology Institute Among Leaders in Minimally Invasive Treatment for Enlarged Prostate
Innovations in Urology | October 2024
New Study Published in NEJM Evidence with UH Seidman Cancer Center Researchers and ArteraAI
Study validates the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer - Innovations in Cancer | Summer 2023
JAMA Study Finds Patients with Prostate Cancer Are Increasingly Choosing Active Surveillance Over Treatment
Active surveillance (AS) is increasingly recognized as the standard of care for low- and some favorable intermediate-risk prostate cancers (PC). - Innovations in Urology | Summer 2023
Community-Engaged Research Combats Breast Cancer and Prostate Cancer
Cynthia Owusu, MD and Randy Vince, MD discuss how they help improve the social determinants of health and health disparities for African American men and women with prostate and breast cancers.
From MMA Fighter to Radiation Oncologist: Combating Prostate Cancer
Daniel Spratt, MD discusses the obstacles of prostate cancer and shares breakthroughs and achievements.
Researchers Find Favorable Tradeoffs of PSA Screening for Prostate Cancer
Data support PSA screening, particularly in Black men, for whom there is a shortage of clinical trial evidence - Innovations in Urology | Summer 2022
Researchers Show Increased Survival Rate in Prostate Cancer Patients with Addition of Hormone Therapy Treatments
First-of-its-kind meta-analysis published in The Lancet Oncology - Innovations in Cancer Winter 2022
UH in the News
- Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt [UroToday]
- The Benefit of ADT Treatment Intensification With Radiotherapy in Localized Prostate Cancer – Dan Spratt and Amar Kishan [UroToday]
- AI-Derived Digital Pathology-Based Biomarker To Predict the Benefit of ADT in Localized Prostate Cancer – Dan Spratt [UroToday]
- Prostate cancer screening is better than originally thought, especially for Black men, study says [CNN]